复星医药 (600196)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

ASH

Tags

300ESG Index300 Non-Cyclical IndexAI HealthcareAI AgentsContract Research Organization (CXO)DeepSeekMSCI Component StocksSSE 180 IndexSSE Mid Cap IndexSSE Corporate Governance IndexCSI 200 IndexGeneric DrugsImmunotherapyWeight Loss DrugsSpin-off ListingsAnalyst Recommended StocksInnovation 100 IndexInnovative DrugsChemical PharmaceuticalsMedical Aesthetics ConceptPharmaceutical ManufacturingPharmaceuticals and HealthcareContains H-SharesGene ConceptCCTV 50 IndexFamily DoctorsSmart HealthcareIntelligent MachinesPrivate Enterprises 100 IndexPrivate HospitalsCSI 300 IndexConsumption 100 IndexBiological VaccinesHigh-Performing StocksMargin Trading and Securities LendingChina Securities Finance and Central Huijin HoldingsAssisted ReproductionNon-Cyclical StocksHigh Accounts Receivable

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 267042.93
  • Circulating A-Shares(W): 211848.88
  • Earnings Per Share(RMB): 0.9500
  • Net Assets Per Share(RMB): 17.9853
  • Operating Revenue(W RMB): 2939338.54
  • Total Profit(W RMB): 383734.35
  • **Net Profit Attributable to Parent(W RMB) **: 252329.35
  • Net Profit Growth Rate(%): 25.50
  • Weighted Return on Equity(%): 5.3000
  • Operating Cash Flow Per Share(RMB): 1.2660
  • Undistributed Profit Per Share(RMB): 10.5728
  • Capital Reserve Per Share(RMB): 6.1172

2. Main Business

The main business covers:

  • Pharmaceutical manufacturing
  • Pharmaceutical sales
  • Medical devices and medical diagnostic products

3. Company Basic Information

  • Company Name: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Listing Date: 1998-08-07
  • Industry: Pharmaceutical manufacturing
  • Address: Building A, 1289 Yishan Road, Shanghai
  • Website: https://www.fosunpharma.com/
  • Company Profile: The company's predecessor was Shanghai Fosun Industrial Co., Ltd., which was restructured into a joint stock company on July 13, 1998. The promoters contributed their net assets to form 100.70 million promoter shares. After issuing 45 million public shares on June 15, 1998, the total share capital at listing reached 150.70 million shares. The 5 million internal employee shares were listed for trading on the Shanghai Stock Exchange on August 7, 1998, six months after the 45 million public shares were listed.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Shanghai Fosun High Technology (Group) Co., Ltd. General Legal Person 88989.10 42.01
2 Hong Kong Securities Clearing Company Ltd. Northbound Capital 5524.54 2.61
3 China Securities Finance Co., Ltd. Special Legal Person 3873.61 1.83
4 Huatai-Pinebridge CSI 300 ETF Fund 2170.84 1.02
5 China Merchants China Securities Bio-medicine Index (LOF) Fund Class A Fund 1818.55 0.86
6 E Fund CSI 300 Healthcare ETF Fund 1592.71 0.75
7 E Fund CSI 300 ETF Fund 1564.28 0.74
8 Yinhua CSI Innovative Drug Industry ETF Fund 1241.14 0.59
9 Tianhong China Securities Bio-medicine ETF Fund 638.24 0.30
10 GF China Securities Innovative Drug Industry ETF Fund 606.50 0.29

5. Concept Sectors

  • H-Share
  • Biological Vaccine
  • Private Hospital
  • Intelligent Machinery
  • Gene Concept
  • Immunotherapy
  • Intelligent Healthcare
  • Generic Drugs
  • Medical Aesthetics Concept
  • CXO Concept
  • Assisted Reproduction
  • Family Doctor
  • Innovative Drugs
  • Weight Loss Drugs
  • AI Agent
  • DeepSeek
  • AI Healthcare

Remarks

  • Data update date: 2025-11-02
  • Data source: Public market information